Orginal Article |
|
|
|
|
Characteristics and Prognostic Significance of Ki-67 Expression at diagnosis in Adult t(8;21) Acute Myeloid Leukemia |
DAO Feng-ting,YANG Lu,WANG Ya-zhe,CHANG Yan,YUAN Xiao-ying,LI Ling-di,CHEN Wen-min,LONG Ling-yu,LIU Yan-rong,QIN Ya-zhen() |
Peking University Peoples’ Hospital, Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease, Beijing China,100044 |
|
|
Abstract Objective: To investigate the characteristics and prognostic significance of Ki-67 antigen expression at diagnosis in adult t(8;21) acute myeloid leukemia (AML).Methods: Bone marrow samples of 57 adult t(8;21) AML patients were collected at diagnosis from July 2012 to February 2019 in our hospital, their frequencies of Ki-67 in CD34 + cells were detected by flow cytometry method, and the relationships between Ki-67 and the biological characteristics, therapeutic effect and relapse were analyzed. Results: Of all patients tested, the median percentage of CD34 +Ki-67 + cells were 30.5% (range: 10.0%~65.8%); A receiver operating characteristic (ROC) curve was used to identify the optimal cutoff levels of CD34 +Ki-67 + cells, higher frequencies of CD34 +Ki-67 + cells were significantly related to higher rate of c-KIT mutation and lower WT1 transcript level at diagnosis (P=0.001; P=0.042). Of all patients followed up, higher frequency of CD34 +Ki-67 + cells was significantly related to a higher 1-year cumulative incidence relapse (CIR) rate (P=0.035). In addition, both lower WT1 transcript level at diagnosis and higher level of minimal residual diseases (MRD, < 3-log reduction of the RUNX1-RUNX1T1 transcript level after the second consolidation therapy) were significantly related to a higher 1-year CIR rate (P<0.000 1; P=0.041), and patients with c-KIT mutation and white blood cell count>10×10 9/L at diagnosis tended to have higher 1-year CIR rates, respectively (P=0.091; P=0.054). Patients simultaneously with high frequency of CD34 +Ki-67 + cells and high MRD levels have a significantly higher 1-year CIR rate than others (P<0.000 1). Conclusion: In adult patients with t(8;21) AML, high frequency of CD34 +Ki-67 + cells at diagnosis may be a poor prognostic factor, combination of MRD levels and frequency of CD34 +Ki-67 + cells at diagnosis may better predict relapse than MRD alone.
|
Received: 22 August 2019
Published: 20 September 2019
|
|
Corresponding Authors:
Ya-zhen QIN
E-mail: qin2000@aliyun.com
|
|
Cite this article:
DAO Feng-ting,YANG Lu,WANG Ya-zhe,CHANG Yan,YUAN Xiao-ying,LI Ling-di,CHEN Wen-min,LONG Ling-yu,LIU Yan-rong,QIN Ya-zhen. Characteristics and Prognostic Significance of Ki-67 Expression at diagnosis in Adult t(8;21) Acute Myeloid Leukemia. China Biotechnology, 2019, 39(9): 11-18.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20190902 OR https://manu60.magtech.com.cn/biotech/Y2019/V39/I9/11
|
|
|
[1] |
Byrd J C, Mrozek K, Dodge R K , et al. Cancer and leukemia Group B(CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B(CALGB 8461). Blood, 2002,100(13):4325-4336.
|
|
|
[2] |
Schlenk R F, Benner A, Krauter J , et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol, 2004,22(18):3741-3750.
|
|
|
[3] |
Marcucci G, Mrózek K, Ruppert A S , et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol, 2005,23(24):5705-5717.
|
|
|
[4] |
Schnittger S, Kohl T M, Haferlach T , et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood, 2006,107(5):1791-1799.
|
|
|
[5] |
Wang Y Y, Zhou G B, Yin T , et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA, 2005,102(4):1104-1109.
|
|
|
[6] |
Qin Y Z, Zhu H H, Jiang Q , et al. Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer J, 2018,8(8):76.
|
|
|
[7] |
Qin Y Z, Wang Y, Zhu H H , et al. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chin J Cancer, 2016,35:46.
|
|
|
[8] |
Jourdan E, Boissel N, Chevret S , et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013,121(12):2213-2223.
doi: 10.1182/blood-2012-10-462879
|
|
|
[9] |
Zhu H H, Zhang X H, Qin Y Z , et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission; results from the AML05 multicenter trial. Blood, 2013,121(20):4056-4062.
doi: 10.1182/blood-2012-11-468348
|
|
|
[10] |
Shevra C R, Ghosh A, Kumar M . Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium. J Postgrad Med, 2015,61(1):15-20.
|
|
|
[11] |
Zheng J N, Pei D S, Mao L J , et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther, 2009,16(1):20-32.
|
|
|
[12] |
He X, Chen Z, Fu T , et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer, 2014,14:153.
|
|
|
[13] |
Vose J M . Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol, 2013,88(12):1082-1088.
|
|
|
[14] |
Xu P, Yu D, Wang L , et al. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single——institution study of 105 Chinese patients. Ann Hematol, 2015,94(2):239-247.
|
|
|
[15] |
Shome D K, Khurana N . Distinctive AgNOR patterns of myeloid and lymphoid blasts in acute leukemia. Am J Hematol, 1999,61(2):149-152.
|
|
|
[16] |
王喜安, 金冠球, 肖正达 , 等. 白血病细胞Ki-67表达和Ag-NORs计数及其临床意义. 白血病·淋巴瘤, 2001,10(1):22-24.
|
|
|
[16] |
Wang X A, Jin G Q, Xiao Z D , et al. Ki-67 expression and Ag-NORs count of leukemia cells and its clinical significance. Leukemia · Lymphoma, 2001,10(1):22-24.
|
|
|
[17] |
Sun X, Medeiros L J, Lu D , et al. Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16) (p13q22). Am J Clin Pathol, 2003,120(2):236-245.
|
|
|
[18] |
Nowicki M, Ostalska-Nowicka D, Miskowiak B . Prognostic significance of Ki67-negative blast cell clone in the high risk group of children treated for acute myeloid leukemia. Folia Histochem Cytobiol, 2006,44(1):49-52.
|
|
|
[19] |
Han K, Kahng J, Kim M , et al. Expression of functional markers in acute nonlymphoblastic leukemia. Acta Haematol, 2000,104(4):174-180.
|
|
|
[20] |
Kaaijk P, Kaspers G J , Van Wering E R, et al. Cell proliferation is related to in vitro drug resistance in childhood acute leukemia. Br J Cancer, 2003,88(5):775-781.
|
|
|
[21] |
施均, 邵宗鸿, 刘鸿 , 等. 骨髓增生异常综合征患者骨髓细胞周期及CD34 +细胞增殖特征的研究 . 中华血液学杂志, 2004,25(11):641-644.
|
|
|
[21] |
Shi J, Shao Z H, Liu H , et al. Study on the characteristics of cell cycle and proliferation of CD34 + hematopoietic stem cells in myelodysplastic syndromes . Chinese Journal of Hematology, 2004,25(11):641-644.
|
|
|
[22] |
杨文群 . Ki-67、P-gp在急性白血病中的表达及意义. 长沙: 中南大学, 2011.
|
|
|
[22] |
Yang W Q . The expression and significance of Ki-67 and P-gp in patients with acute leukemia. Changsha: Central South University, 2011.
|
|
|
[23] |
王敏, 王立茹 . Ki-67在急性髓系白血病中的研究进展. 中华实验血液学, 2016,24(4):1264-1268.
|
|
|
[23] |
Wang M, Wang L R . Research progress of Ki-67 in acute myeloid leukemia. J Exp Hematol, 2016,24(4):1264-1268.
|
|
|
[24] |
Jothilingam P, Basu D, Dutta T K . Angiogenesis and proliferation index in patients with acute leukemia: a prospective study. Bone Marrow Res, 2014,2014:634874.
|
|
|
[25] |
Staber P B, Linkesch W, Zauner D , et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene, 2004,23(4):894-904.
|
|
|
[26] |
Grimwade D, Walker H, Oliver F , et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood, 1998,92(7):2322-2333.
|
|
|
[27] |
Bloomfield C D, Lawrence D, Byrd J C , et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res, 1998,58(18):4173-4179.
|
|
|
[28] |
Besmer P, Murphy J E, George P C , et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature, 1986,320(6061):415-421.
|
|
|
[29] |
Furitsu T, Tsujimura T, Tono T , et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest, 1993,92(4):1736-1744.
|
|
|
[30] |
Ho P A, Kuhn J, Gerbing R B , et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol, 2011,29(6):704-711.
doi: 10.1200/JCO.2010.31.9327
|
|
|
[31] |
Miglino M, Colombo N, Pica G , et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma, 2011,52(10):1961-1969.
|
|
|
[32] |
Damm F, Heuser M, Morgan M , et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood, 2011,117(17):4561-4568.
doi: 10.1182/blood-2010-08-303479
|
|
|
[33] |
Nomdedéu J F, Hoyos M, Carricondo M , et al. Bone marrow WT1 levels at diagnosis, post-induction and postintensification in adult de novo AML. Leukemia, 2013,27(11):2157-2164.
doi: 10.1038/leu.2013.111
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|